{'fraction_non_alphanumeric': 0.025423728813559324, 'fraction_numerical': 0.012711864406779662, 'mean_word_length': 5.654929577464789, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Maintenance of Antibody Avidity in Alaska Native Adolescents Receiving Quadrivalent Human Papillomavirus (HPV) Vaccine

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide, and some types are causally associated with cervical and other types of cancers in women and men. Currently available prophylactic anti‐HPV vaccines are highly effective, eliciting high antibody titers. In the United States, the most commonly used HPV vaccine through 2015 was quadrivalent vaccine (4vHPV), which protects against HPV types 6, 11, 16, and 18. However, the minimum antibody threshold required for protection has not been established. Antibody avidity, a measure of how strongly antibodies bind their cognate antigen, is associated with clearance of many pathogens, and has been proposed as an additional measure of antibody activity against HPV. Few antibody avidity studies have been conducted on HPV vaccine recipients.